New antibody HX009 shows promise for tough lymphoma cases
NCT ID NCT05189093
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called HX009 in 48 Chinese patients with lymphoma that had relapsed or not responded to prior treatments. HX009 is a dual-target antibody designed to block two proteins (CD47 and PD-1) that help cancer cells hide from the immune system. The goal was to see if the drug could shrink tumors and how safe it was. The trial has been completed, and results will help determine if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HX009 (a dual-target antibody that blocks CD47 and PD-1 proteins on cancer cells)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with lymphoma that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciense
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New drug cocktail aims to tackle tough lymphoma
- New hope for tough lymphoma: Three-Drug showdown begins